200 related articles for article (PubMed ID: 28211784)
1. Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries?
.
Cattaneo D; Andreoni M; Carosi G; Cauda R; Lazzarin A; Rizzardini G
Int J Clin Pharmacol Ther; 2017 May; 55(5):381-393. PubMed ID: 28211784
[TBL] [Abstract][Full Text] [Related]
2. Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reduction.
Ramiro MA; Llibre JM
Enferm Infecc Microbiol Clin; 2014 Nov; 32(9):598-602. PubMed ID: 24139337
[TBL] [Abstract][Full Text] [Related]
3. The future of generic HIV drugs in Rhode Island.
Lee JY; Reece R; Montague B; Rana A; Alexander-Scott N; Flanigan T
R I Med J (2013); 2013 Sep; 96(9):30-3. PubMed ID: 24015398
[TBL] [Abstract][Full Text] [Related]
4. Generic substitution of antiretrovirals: patients' and health care providers' opinions.
Kieran JA; O'Reilly E; O'Dea S; Bergin C; O'Leary A
Int J STD AIDS; 2017 Oct; 28(12):1239-1246. PubMed ID: 28632475
[TBL] [Abstract][Full Text] [Related]
5. The impact of visa status and Medicare eligibility on people diagnosed with HIV in Western Australia: a qualitative report.
Herrmann S; Wardrop J; John M; Gaudieri S; Lucas M; Mallal S; Nolan D
Sex Health; 2012 Nov; 9(5):407-13. PubMed ID: 22950904
[TBL] [Abstract][Full Text] [Related]
6. The financial and service implications of splitting fixed-dose antiretroviral drugs - a case study.
Taylor R; Carlin E; Sadique Z; Ahmed I; Adams EJ
Int J STD AIDS; 2015 Feb; 26(2):75-80. PubMed ID: 24700200
[TBL] [Abstract][Full Text] [Related]
7. Scaling-up the use of generic antiretrovirals in resource-limited countries: generic drugs for health.
Beck EJ; Passarelli C; Lui I; Guichard AC; Simao M; De Lay P; Loures L
Antivir Ther; 2014; 19 Suppl 3():117-23. PubMed ID: 25310477
[TBL] [Abstract][Full Text] [Related]
8. Laboratory monitoring of HIV--after access to antiretroviral drugs, the next challenge for the developing world.
Tucker T; Yeats J
S Afr Med J; 2001 Aug; 91(8):615. PubMed ID: 11584766
[No Abstract] [Full Text] [Related]
9. Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy.
Llibre JM; Arribas JR; Domingo P; Gatell JM; Lozano F; Santos JR; Rivero A; Moreno S; Clotet B;
AIDS; 2011 Sep; 25(14):1683-90. PubMed ID: 21673556
[TBL] [Abstract][Full Text] [Related]
10. Generic immunosuppression in solid organ transplantation: a Canadian perspective.
Harrison JJ; Schiff JR; Coursol CJ; Daley CJ; Dipchand AI; Heywood NM; Keough-Ryan TM; Keown PA; Levy GA; Lien DC; Wichart JR; Cantarovich M
Transplantation; 2012 Apr; 93(7):657-65. PubMed ID: 22267158
[TBL] [Abstract][Full Text] [Related]
11. Access to essential medications for HIV/AIDS in South Africa.
Andrews S
S Afr Med J; 2001 May; 91(5):384-7. PubMed ID: 11455797
[No Abstract] [Full Text] [Related]
12. [HIV infection and AIDS from the health policy viewpoint. Savings and therapy superiority maintained - a contradiction in HIV therapy?].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():62-3. PubMed ID: 25026863
[No Abstract] [Full Text] [Related]
13. What Is the Future of Generics in Transplantation?
van Gelder T
Transplantation; 2015 Nov; 99(11):2269-73. PubMed ID: 26050017
[TBL] [Abstract][Full Text] [Related]
14. Generic antiretroviral drugs and HIV care: An economic review.
Yazdanpanah Y; Schwarzinger M
Med Mal Infect; 2016 Mar; 46(2):67-71. PubMed ID: 26905394
[TBL] [Abstract][Full Text] [Related]
15. Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort.
Stoll M; Kollan C; Bergmann F; Bogner J; Faetkenheuer G; Fritzsche C; Hoeper K; Horst HA; van Lunzen J; Plettenberg A; Reuter S; Rockstroh J; Stellbrink HJ; Hamouda O; Bartmeyer B;
PLoS One; 2011; 6(9):e23946. PubMed ID: 21931626
[TBL] [Abstract][Full Text] [Related]
16. Utilization and costs of HIV antiretroviral drugs in Europe during the last ten years: Impact of generic antiretroviral drugs on cost reduction.
Rwagitinywa J; Sommet A; Palmaro A; Montastruc JL; Lapeyre-Mestre M
Health Policy; 2018 Mar; 122(3):237-242. PubMed ID: 29398158
[TBL] [Abstract][Full Text] [Related]
17. Global challenges in the development and delivery of paediatric antiretrovirals.
Bowen A; Palasanthiran P; Sohn AH
Drug Discov Today; 2008 Jun; 13(11-12):530-5. PubMed ID: 18549980
[TBL] [Abstract][Full Text] [Related]
18. TRIPS post-2005 and access to new antiretroviral treatments in southern countries: issues and challenges.
Orsi F; D'Almeida C; Hasenclever L; Camara M; Tigre P; Coriat B
AIDS; 2007 Oct; 21(15):1997-2003. PubMed ID: 17885289
[No Abstract] [Full Text] [Related]
19. Potential Clinical and Economic Impact of Switching Branded Medications to Generics.
Straka RJ; Keohane DJ; Liu LZ
Am J Ther; 2017 May; 24(3):e278-e289. PubMed ID: 26099048
[TBL] [Abstract][Full Text] [Related]
20. Low-cost generic drugs under the President's Emergency Plan for AIDS Relief drove down treatment cost; more are needed.
Venkatesh KK; Mayer KH; Carpenter CC
Health Aff (Millwood); 2012 Jul; 31(7):1429-38. PubMed ID: 22778332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
